Preclinical evaluation of modern
oral dosage forms requires more
advanced in vitro devices as the trend of selecting low solubility,
high permeability compounds for commercial development continues.
Current dissolution methodologies may not always be suitable for such
compounds due to excessive fluid volume, high fluid shear rates, heterogeneity
of shear rates, suboptimal fluid flow, and, ultimately, the lack of
absorption ability (The Science of USP 1 and 2 Dissolution:
Present Challenges and Future Relevance
Gray
Pharmaceutical
Research20092612891302). Herein, a new
dissolution apparatus is introduced in combination with an ultrathin,
semipermeable polymer membrane that mimics human passive absorption
for lipophilic compounds. The ultrathin large-area polydimethylsiloxane
(PDMS) membrane (UTLAM) absorption system is designed to mimic the
dissolution and passive transcellular diffusion process representing
the oral absorption pathway. A simple spin-casting method was developed
to fabricate the ultrathin highly uniform membranes. To minimize membrane
resistance to diffusion and maximize transport across the polymer
membrane, 10–40 μm PDMS membranes were successfully prepared.
A new diffusion cell was designed and tested to support the UTLAM
and incorporates a hydrofoil impeller for more desirable hydrodynamics
and mixing, using ibuprofen as a model weak acidic drug. UTLAM permeability
was sufficiently high that the aqueous boundary layer contributed
to the overall permeability of the system. This diffusion cell system
demonstrated that, when the aqueous diffusion layer contributes to
the overall resistance to transport, the pH at which absorption is
50% of maximum (pH50%) shifts from the pK
a to higher values, demonstrating why weak acid drugs
can exhibit high absorption at pH’s significantly greater than
their pK
a. High rates of transport across
the UTLAM are possible for drugs with high partition coefficients
(i.e., BCS II compounds even under mostly ionized conditions), and
PDMS UTLAMs may be tailored to simulate human intestinal passive absorption
rates.